VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC

1 hour ago 4

Exec-Edge

Thu, May 28, 2026 astatine 11:53 AM CDT 1 min read

By Karen Roman

VERAXA Biotech AG said it has a securities acquisition statement with an organization capitalist for $27.5 million, abstracted to a $50 cardinal stock acquisition statement with Lincoln Park Capital Fund.

The institution besides applied for a Nasdaq listing nether the ticker awesome “VRXA” via a combination with Voyager Acquisition Corp. (Nasdaq: VACH) and to beforehand its crab therapies pipeline, VERAXA stated.

“Securing these financings marks a important measurement successful our ongoing concern operation with Voyager Acquisition Corp. and the expected listing of VERAXA shares connected NASDAQ,” said Torsten Bürgermeister, VERAXA’s CFO. “We admit the fiscal enactment of these investors arsenic we proceed to employment a disciplined attack to equilibrium expanse absorption done businesslike and flexible entree to capital.”d

READ MORE